Neurobiologic Insights into Major Depressive Disorder: An Update on Emerging Therapies with Novel Mechanisms of Action

Neurobiologic Insights into Major Depressive Disorder: An Update on Emerging Therapies with Novel Mechanisms of Action is organized by Healthcare Made Practical (HMP) Communications LLC and will be held from Nov 30, 2018 - Nov 30, 2019.

Intended Learners:
This Activity Is Intended For Psychiatrists, Primary Care Physicians, Psychologists, Physician Assistants, Psychiatric Nurses, And Other Healthcare Professionals Who Seek To Improve The Care Of Patients With Mental Health Disorders.

Accreditation:
CME:Naccme Designates This Enduring Material For A Maximum Of 1.25 Ama Pra Category 1 Credits™. Physicians Should Claim Only The Credit Commensurate With The Extent Of Their Participation In The Activity.

Physician Assistants: Naccme Has Been Authorized By The American Academy Of Pas (Aapa) To Award Aapa Category 1 CME Credit For Activities Planned In Accordance With The Aapa Cme Criteria. This Activity Is Designated For 1.25 Aapa Category 1 Credit(S). Pas Should Only Claim Credit Commensurate With The Extent Of Their Participation In The Activity.

CNE: This Continuing Nursing Education Activity Awards 1.25 Contact Hours. Provider Approved By The California Board Of Registered Nursing, Provider #13255 For 1.50 Contact Hours.

Nursing Pharmacology Hours: This Continuing Nursing Educational Activity Awards Up To 1.25 Pharmacology Hours.

Learning Objectives:
After Completing This Activity, Participants Should Be Able To:
• Outline the significant prevalence and burden of major depressive disorder (MDD) and the limitations of current pharmacotherapeutic approaches to management
• Discuss the current understanding of MDD pathophysiology with respect to the neurobiological  pathways involved and potential therapeutic targets
• Evaluate the clinical and pharmacologic data surrounding MDD pharmacotherapies in late-stage development, in terms of their mechanisms of action, efficacy, and safety in treatment-resistant depression
• Discuss how these novel pharmacotherapies may expand options for evidence-based management of MDD